Innovation
DETERA Therapeutics, a peptide to prevent crescentic glomerulonephritis (CGN)
… more than fifteen years," emphasises Lyse Santoro. Their project convinced SATT Paris-Saclay, which ensured its … funding the following month. In June 2025, the start-up was selected by Bpifrance to join the deep tech community. DETERA was also a finalist for the IPSEN Golden Ticket. The three …
Published on: